Together, we work to accelerate innovation, enhance patient access to medicines, build an inclusive, diverse and equitable work environment, and strengthen our environmental sustainability — all while operating with the highest levels of quality, integrity and ethics.

50 years of science and changing lives

For half a century, Genentech's passion for science has driven us to explore uncharted territory, leading to groundbreaking discoveries that have fundamentally changed the lives of patients and reduced the burden of complex health challenges on society.

Genmab is an international biotechnology company focused on developing innovative antibody-based medicines to transform the treatment of cancer and other serious diseases. With patients at the center of its work, Genmab combines deep expertise in antibody science with innovative technologies to develop new and potentially transformative treatment options. Founded in 1999, Genmab continues to advance oncology research through its own discoveries and collaborations with partners around the world.

Our commitment to Solve On. speaks to what motivates us to find answers for patients. It inspires us to bring advances for those with unmet needs, and it reminds us that patients are waiting. That spirit, energy and excitement are felt across the company each day.

Since our start in 2002 with a small number of scientists, chemists and biologists in Wilmington, Delaware, Incyte has grown into a global organization with a robust portfolio of treatments across Hematology, Oncology and Inflammation and Autoimmunity. Today this passion for innovation is stronger than ever with a team of more than 2,800 employees with operations in North America, Europe and Asia.

Our purpose: We use the power of leading-edge science to save and improve lives around the world

For more than 130 years, we’ve brought hope to humanity through the development of important medicines and vaccines. We foster an inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.

Stemline Therapeutics, a part of the Menarini Group, is focused on the development and commercialization of novel oncology therapeutics.

The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and commercializing novel first-in-class therapeutics.

ELZONRIS® (tagraxofusp), a targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years or older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In Europe, the European Medicines Agency (EMA) approved ELZONRIS in January 2021. ELZONRIS is also being evaluated in clinical trials in additional indications including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and myelofibrosis (MF).

ORSERDU (elacestrant) is a selective estrogen receptor degrader (SERD) FDA approved for the treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Studies completed to date, including the positive results from the pivotal EMERALD trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Indeed, ORSERDU is the first FDA approved oral SERD to show positive results in a pivotal, Phase III trial as a monotherapy versus standard of care for the treatment of ER+/ HER2- advanced or metastatic breast cancer.

Stemline is headquartered in New York City.

SILVER SPONSOR

The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development and commercialization of orally administered anti-cancer agents for various tumor types. Taiho Oncology has a robust pipeline of small molecule clinical candidates targeting solid tumor and hematological malignancies, with additional candidates in pre-clinical development. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Baar, Switzerland and Oakville, Ontario, Canada.

Lilly is a medicine company that has been turning science into medicine for 150 years, with a focus on some of the world’s toughest diseases, including cancer. Lilly’s commitment to oncology is rooted in a long history of developing life-changing medicines and supporting people living with cancer and those who care for them.

Today, Lilly continues to advance cancer research with the goal of creating new medicines that can make a difference for people living with cancer. Its research includes treatments for a range of cancers, including rare cancers, as well as approaches tailored to individual patients.

BRONZE SPONSOR

Driven to Do More

Every day, we come to work focused and driven by the opportunity to deliver the next best-in-class therapy for patients with genetically defined diseases – to move beyond incremental improvements and solely treating symptoms, to address the real causes of disease. We are methodical, rational, and intentional in our approach to identify pragmatic solutions to complex health challenges with the goal of restoring health and allowing patients to live better, longer lives.